Intragastric Balloon Significantly Improves Metabolic Parameters at 6 Months: a Meta-Analysis

Shah, Rahil H.; Vedantam, Shyam; Kumar, Shria; Amin, Sunil; Pearlman, Michelle; Bhalla, Sean

doi:10.1007/s11695-022-06437-7

Cited by 4 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent meta-analysis showed that RYGB results in greater 12-month body weight and fat loss, but similar losses in lean mass, compared with adjustable gastric band, although this was based on only two RCTs [ 220 ]. Non-surgical intragastric balloons, involving endoscopic insertion of a silicon fluid-filled balloon into the stomach causing earlier feelings of satiety [ 221 ], also lead to lean mass losses [ 222 ], despite improving glycemic control [ 223 ]. Maintaining muscle mass should therefore be a key focus following BS.…”

Section: Interventions For Improving Metabolic and Muscle Healthmentioning

confidence: 99%

Type 2 Diabetes Mellitus and Sarcopenia as Comorbid Chronic Diseases in Older Adults: Established and Emerging Treatments and Therapies

Mesinovic,

Fyfe,

Talevski

et al. 2023

Diabetes Metab J

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) and sarcopenia (low skeletal muscle mass and function) share a bidirectional relationship. The prevalence of these diseases increases with age and they share common risk factors. Skeletal muscle fat infiltration, commonly referred to as myosteatosis, may be a major contributor to both T2DM and sarcopenia in older adults via independent effects on insulin resistance and muscle health. Many strategies to manage T2DM result in energy restriction and subsequent weight loss, and this can lead to significant declines in muscle mass in the absence of resistance exercise, which is also a first-line treatment for sarcopenia. In this review, we highlight recent evidence on established treatments and emerging therapies targeting weight loss and muscle mass and function improvements in older adults with, or at risk of, T2DM and/or sarcopenia. This includes dietary, physical activity and exercise interventions, new generation incretin-based agonists and myostatin-based antagonists, and endoscopic bariatric therapies. We also highlight how digital health technologies and health literacy interventions can increase uptake of, and adherence to, established and emerging treatments and therapies in older adults with T2DM and/or sarcopenia.

show abstract

Section: Interventions For Improving Metabolic and Muscle Healthmentioning

confidence: 99%

Type 2 Diabetes Mellitus and Sarcopenia as Comorbid Chronic Diseases in Older Adults: Established and Emerging Treatments and Therapies

Mesinovic,

Fyfe,

Talevski

et al. 2023

Diabetes Metab J

View full text Add to dashboard Cite

show abstract

“…17 A subsequent 2023 meta-analysis further linked IGBs with improvements in insulin resistance, blood pressure, and dyslipidemia. 19 The IGBs from the different manufacturers differ in their configurations, dimensions, and the number of balloons introduced. Here, the Orbera placement procedure, a popular global choice recently adopted in Korea, is described (Fig.…”

Section: Intragastric Balloon Placementmentioning

confidence: 99%

Endoscopic Bariatric Therapy for Obesity and Metabolic Syndrome

Lee

2023

Korean J Helicobacter Up Gastrointest Res

View full text Add to dashboard Cite

Globally, the prevalence of obesity and its associated comorbidities is increasing. Traditionally, the primary modalities for the treatment of obesity have included lifestyle interventions, pharmacological approaches, and bariatric surgery. However, endoscopic bariatric therapy, a more recent development, is emerging as a significant tool for the management of obesity and metabolic disorders. This review seeks to elucidate the latest advancements in metabolic bariatric endoscopy, highlighting their respective merits and limitations and offering insights into potential future research directions.

show abstract

Intragastric Balloon as a First Step Before Metabolic Bariatric Surgery in Patients with BMI ≥ 50 kg/m2: are the Results After Balloon Related to Global Outcomes After Surgery?

Pinho,

Manco,

Silva

et al. 2024

OBES SURG

View full text Add to dashboard Cite

Introduction Patients with body mass index (BMI) ≥ 50 kg/m2, classified with obesity class IV/V, require complex treatments. Intragastric balloon (IGB) is a possible treatment before metabolic bariatric surgery (MBS) that may reduce peri-operative complications. This study evaluates IGB outcomes and complications before MBS in patients with Obesity IV/V, and subsequent MBS results, regarding weight loss and comorbidity resolution. Methods Retrospective cohort study of all patients with BMI above 50 kg/m2 submitted to IGB before MBS between 2009 and 2023 in a high-volume center. Variables analyzed included weight loss after IGB and MBS, IGB complications, and comorbidity resolution. Suboptimal clinical responses were defined as %TWL < 5% for IGB, %TWL < 20% for MBS, and %TWL < 25% or BMI ≥ 35 kg/m2 for IGB + MBS. Results Seventy-four patients (mean BMI 58.8 ± 8 kg/m2) were included. After IGB, the mean %TWL was 14.2 ± 8.5%, with a 21.6% complication rate, predominantly nausea and vomiting, and one death. Suboptimal clinical response of IGB affected 13.5% of patients, and 5.4% required early removal. Two years after MBS, the mean %TWL was 38.2 ± 11.6%, mainly due to MBS, yet approximately one-third of %TWL was attributed to IGB. No correlation was found between IGB and MBS outcomes. At 2-year follow-up, 45.1% patients had %TWL ≥ 25 and BMI < 35 kg/m2. Conclusion The IGB is a treatment option before MBS in patients with Obesity Class IV/V, with acceptable weight loss outcomes but not infrequent complications. A multidisciplinary approach is mandatory, and all treatments must be considered in this difficult subset of patients. Graphical Abstract

show abstract

Intragastric Balloon Significantly Improves Metabolic Parameters at 6 Months: a Meta-Analysis

Cited by 4 publications

References 45 publications

Type 2 Diabetes Mellitus and Sarcopenia as Comorbid Chronic Diseases in Older Adults: Established and Emerging Treatments and Therapies

Type 2 Diabetes Mellitus and Sarcopenia as Comorbid Chronic Diseases in Older Adults: Established and Emerging Treatments and Therapies

Endoscopic Bariatric Therapy for Obesity and Metabolic Syndrome

Intragastric Balloon as a First Step Before Metabolic Bariatric Surgery in Patients with BMI ≥ 50 kg/m2: are the Results After Balloon Related to Global Outcomes After Surgery?

Contact Info

Product

Resources

About